Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Alert-HF: Early Detection and Intervention on Atrial Fibrillation in Heart Failure Patients (Alert-HF)

5 novembre 2026 mis à jour par: Medisch Spectrum Twente

The goal of this clinical trial is to learn if using remote heart rhythm monitoring strategies can reduce unplanned cardiac care utilization and improve health-related quality of life in adults with heart failure (HF). It focuses on adults with heart failure who have no history of an irregular heartbeat called atrial fibrillation (AF) and do not have an existing pacemaker or implantable defibrillator.

The main questions the trial aims to answer are:

  • Does a continuous rhythm monitor placed under the skin or a patient-driven portable home device decrease unplanned cardiac care utilization?
  • Do these rhythm monitoring strategies influence therapeutic management?
  • Do these rhythm monitoring strategies improve patient-reported quality of life and overall survival?

Researchers will compare two monitoring groups to a standard care group over an 18-month period to see which approach works best in heart failure treatment

Participants will:

  • either have a small heart monitor placed under their chest skin for heart rhythm observation (arm 1), use a handheld device to take regular heart recordings at home (arm 2) or follow standard care (arm 3) for a period of 18 months
  • Answer a health survey at the start of the study and after 18 months of follow-up.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

266

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Adult patients with HF and no history of documented AF on electrocardiogram (ECG)

Exclusion Criteria:

  • Patients with CIED, such as an implantable cardioverter defibrillator (ICD), Cardiac Resynchronization Therapy Defibrillator (CRT-D), or pacemaker.
  • Documented AF before inclusion
  • Admission to hospices or palliative care
  • Inability to communicate in Dutch or English.
  • Participant under the age of 18 years old
  • Participant is pregnant
  • Mental disorders that, according to the treating physician, make participation unsafe

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Arm 1: Hospital-driven continuous monitoring with an implantable loop recorder

Arm 1: Hospital-driven continuous rhythm monitoring with an implantable loop recorder (ILR) placed subcutaneously in the left pectoral region.

Hospital-driven continuous monitoring with an implantable loop recorder

Comparateur actif: Arm 2: Patient-driven portable ECG monitoring

Patient-driven single-lead portable ECG monitoring in which patients are instructed to send ECG recordings of at least 30 seconds both on a scheduled routine basis and whenever experiencing symptoms suggestive of an arrhytmia.

Patient-driven portable ECG monitoring

Comparateur actif: Arm 3: Usual Care

All patients are treated according to the ESC guidelines (ESC HF 2026). This includes periodic outpatient utilization.

Usual care

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Number of unplanned cardiac care utilization
Délai: 18 months

Unplanned cardiac healthcare utilization will be assessed through systematic review of patients' medical records. The number of healthcare episodes occurring during the study observation period will be recorded. Each unique healthcare episode will be classified according to the principal setting of care: outpatient clinic, daycare/day-case admission, emergency care without admission, or hospitalization. Both total and stratified care utilization will be reported.

An episode will be considered unplanned when healthcare is initiated in response to an acute, unexpected, worsening, or urgent cardiac health problem.

Healthcare episodes involving transfers between care settings as part of the same continuous episode will be counted once and classified according to the highest level of care reached, to avoid double counting.

18 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Number of planned cardiac care utilization
Délai: 18 months

Planned healthcare utilization comprises healthcare episodes scheduled or arranged in advance for routine, preventive, diagnostic, therapeutic, monitoring, rehabilitation, or follow-up care. This includes planned hospitalizations, planned daycare/day-case encounters, and planned outpatient clinic visits.

18 months
Time from inclusion to first diagnosis of AF
Délai: 18 months

The clinical diagnosis of AF by a healthcare professional must be supported by ECG documentation demonstrating AF on a single-lead recording of at least 30 seconds or a standard 12-lead ECG, obtained using the assigned monitoring device or as part of routine clinical care.

18 months
The number of participants diagnosed with AF according to the electronic health rercords (EHR)
Délai: 18 months

AF diagnosis will be established based on electrocardiographic (ECG) documentation obtained either through the assigned monitoring strategy or as part of routine clinical care, as assessed by a qualified healthcare professional.

18 months
Number of AF-related pharmacological and non-pharmacological management changes
Délai: 18 months

Pharmacological changes include initiation, discontinuation, dose increase, dose decrease or switching of oral anticoagulants (OAC) and rate- and/or rhythm-control medications, including antiarrhythmic drugs.

Non-pharmacological interventions include electrical or pharmacological cardioversion, catheter ablation and AF-related CIED implantation or reprogramming.

The number of management changes will be grouped according to the treatment type and type of adjustment.

18 months
Number of HF-related pharmacological and non-pharmacological management changes during the study observation period.
Délai: 18 months

Pharmacological changes include initiation, discontinuation, dose increase, dose decrease or switching of guideline-directed medical therapy (GDMT), including ARNI/ACEi/ARB, beta-blockers, mineralocorticoid receptor antagonists (MRA), sodium-glucose cotransporter-2 inhibitors (SGLT2i) and diuretics.

Non-pharmacological interventions include HF-related CIED implantation or device reprogramming.

The number of management changes will be grouped according to the treatment type and type of adjustment.

18 months
Number of overall arrhythmia diagnosis extracted from EHR
Délai: 18 months

Number of overall arrhythmia diagnosis

18 months
Changes in Quality of life from baseline to 18 months follow-up as assessed by the Quality of life Kansas City Cardiomyopathy Questionnaire
Délai: 18 months

The Kansas City Cardiomyopathy Questionnaire (KCCQ-12) will be collected at baseline and 18 months.

The scores are represented on a scale from 0 to 100 points, where lower scores represent more severe symptoms and higher scores less or no symptoms.

18 months
Change in heart failure-related quality of life from baseline to 18-month follow-up, as assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ).
Délai: 18 months

The Kansas City Cardiomyopathy Questionnaire (KCCQ-12) will be collected at baseline and 18 months.

The scores are represented on a scale from 0 to 100 points, where lower scores represent more severe symptoms and higher scores less or no symptoms.

18 months
Changes in overall Quality of Life from baseline to 18 months follow-up as assessed by the EuroQol 5-Dimension 5-Level (EQ-5D-5L)
Délai: 18 months

The EQ-5D-5L is a standardized questionnaire assessing health-related quality of life across five dimensions on a score from 1 to 5, with one no problems to a score of five with extreme problems on that domain. This allows for direct comparison between baseline and follow-up. The questionnaire also includes a visual analogue scale (EQ-VAS), ranging from 0 (worst imaginable health) to 100 (best imaginable health), on which participants rate their overall health.

Furthermore, responses are used to calculate a health utility index score with values between 0 and 1. 0 indicates life valuation equal to death and one full health.

18 months
Mortality
Délai: 18 months

Mortality

18 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 janvier 2027

Achèvement primaire (Estimé)

1 juin 2029

Achèvement de l'étude (Estimé)

1 juin 2029

Dates d'inscription aux études

Première soumission

7 septembre 2026

Première soumission répondant aux critères de contrôle qualité

7 septembre 2026

Première publication (Réel)

11 septembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

10 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

5 novembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner